EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Use of inhaled ciclesonide for treatment of moderate asthma in Thoroughbred racehorses

Macarena G Sanz iD, Georgia Jellen, Lauren Cody, Jenyka Bergsma, Mandy Cha, Clark Kogan, Gordon Kordas, Warwick M Bayly iD, Renaud Leguillette iD

Journal of Veterinary Internal Medicine · 2025

DOI: 10.1111/jvim.17267 ↗

At a glance

Journal article in Journal of Veterinary Internal Medicine, 2025. Written by Macarena G Sanz and 8 co-authors. Institution: Washington State University, College of Veterinary Sciences, Pullman, Washington, USA. Major MEDLINE topics: Asthma, Horse Diseases, Pregnenediones, Anti-Asthmatic Agents. Cited 3 times so far (Crossref); 45 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Boehringer Ingelheim Animal Health, University of Calgary, Washington State University.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Mild-moderate asthma is common in horses. Inhaled ciclesonide has been approved only for treatment of severe asthma in horses. Hypothesis/Objectives We hypothesized that a 10-day treatment course of inhaled ciclesonide (Aservo EquiHaler) would improve clinical signs, endoscopic tracheal mucus scores, and bronchoalveolar lavage fluid (BALF) cytology in racehorses with moderate asthma. Animals Racehorses with moderate asthma housed at the Emerald Downs Racetrack in Auburn, WA.

Methods

Prospective, randomized, double-blinded, placebo-controlled clinical study. Horses received inhaled ciclesonide (n = 12) or placebo (n = 9) for 10 days. Clinical signs were assessed at different times using the Tesarowski and HOARSI scores and cough during exercise. Endoscopy scoring, BALF cytology, and BALF cell selected gene expression (RT-qPCR) were assessed on Days 0 and 10. Linear and ordinal simple and mixed effects models were used to analyze the data using R statistical software. Significance was set at P < .05.

Results

Only treated horses showed a decrease over time in HOARSI (P ≤ .001), cough (P = .001; −2.83 [−4.37, −1.29]), mast cell % (P = .03; −2.68 [−4.36, −1.0]) and relative expression of IL-6 (P = .002; 0.44 [0.04, −6.99]) and IL-13 (P = .03; 0.52 [0.04, −7.89]) in BAL cells. Treated horses had lower HOARSI (P = .002; −1 [1, 1]) and mast cell % (P = .02; −2.96 [−5.52, −0.39]) on Day 10. Conclusion and Clinical Importance Treatment with inhaled ciclesonide improved clinical signs and decreased BALF mastocytic inflammation in racehorses with moderate asthma without change in the environment. Treatment effect on neutrophilic or eosinophilic asthma remains undetermined. The small number of horses was a study limitation.

Subjects

MeSH terms (MEDLINE)

AsthmaHorse DiseasesPregnenedionesAnti-Asthmatic AgentsAnimalsHorsesBronchoalveolar Lavage FluidAdministration, InhalationFemaleDouble-Blind MethodMaleProspective Studies

Author keywords

Aservo EquiHalerbronchoalveolar lavagecorticosteroidscytokinesendoscopymastocytestracheal mucus

Substances

PregnenedionesciclesonideAnti-Asthmatic Agents

Authors and institutions

  • Washington State University, College of Veterinary Sciences, Pullman, Washington, USA.
  • Faculty of Veterinary Sciences, University of Calgary, Calgary, Alberta, Canada.
  • Cavalli Equine Veterinary Services, Auburn, Washington, USA.
  • Simkins and Tingdale, Inc., Auburn, Washington, USA.
  • StatsCraft LLC, Spokane, Washington 99203, USA.
  • Statistical Consultant, Reno, Nevada, USA.

ORCID profiles: Macarena G Sanz, Warwick M Bayly, Renaud Leguillette

Funding

  • Boehringer Ingelheim Animal Health
  • University of Calgary
  • Washington State University

Cite

APA

Sanz, M. G., Jellen, G., Cody, L., Bergsma, J., Cha, M., Kogan, C., Kordas, G., Bayly, W. M., & Leguillette, R. (2025). Use of inhaled ciclesonide for treatment of moderate asthma in Thoroughbred racehorses. Journal of Veterinary Internal Medicine. https://doi.org/10.1111/jvim.17267

Vancouver

Sanz MG, Jellen G, Cody L, Bergsma J, Cha M, Kogan C, et al. Use of inhaled ciclesonide for treatment of moderate asthma in Thoroughbred racehorses. Journal of Veterinary Internal Medicine. 2025. doi:10.1111/jvim.17267

BibTeX
@article{Sanz2025,
  author = {Sanz, Macarena G and Jellen, Georgia and Cody, Lauren and Bergsma, Jenyka and Cha, Mandy and Kogan, Clark and Kordas, Gordon and Bayly, Warwick M and Leguillette, Renaud},
  title = {Use of inhaled ciclesonide for treatment of moderate asthma in Thoroughbred racehorses},
  journal = {Journal of Veterinary Internal Medicine},
  year = {2025},
  doi = {10.1111/jvim.17267}
}
Start for free →